Liver cancer: Approaching a personalized care

Slides:



Advertisements
Similar presentations
Intermediate stage HCC management
Advertisements

Staging Strategy and Treatment for Patients With HCC
Liver Imaging Reporting and Data System with MR Imaging: Evaluation in Nodules 20 mm or Smaller Detected in Cirrhosis at Screening US Radiology 2015; 275:
HCC Guidelines
EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep
Treatment Strategy for Recurrent Hepatocellular Carcinoma: Salvage Transplantation, Repeated Resection, or Radiofrequency Ablation? Albert C. Y. Chan,
Dr. Mohammed Omar Khalifa
Hepatocellular Carcinoma: Diagnosis and Management
Volume 63, Issue 1, Pages (July 2015)
Volume 46, Issue 3, Pages (March 2007)
The impact of hepatitis E in the liver transplant setting
The Value of Measurement of Circulating Tumor Cells in Hepatocellular Carcinoma Nashwa Sheble, Gehan Hamdy, Moones A Obada, Gamal Y Abouria, Fatma Khalaf.
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Volume 56, Issue 4, Pages (April 2012)
Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies  Gennaro D'Amico, Guadalupe Garcia-Tsao, Luigi.
MELD score is a better prognostic model than Child-Turcotte-Pugh score or Discriminant Function score in patients with alcoholic hepatitis  Wichit Srikureja,
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Primary prevention of variceal haemorrhage: A pharmacological approach
The impact of hepatitis E in the liver transplant setting
Focus on hepatocellular carcinoma
Non-invasive diagnosis of non-alcoholic fatty liver disease
Marcus-Alexander Wörns, Peter Robert Galle  Journal of Hepatology 
Volume 68, Issue 4, Pages (April 2018)
Living donor liver transplantation: is the hype over?
Volume 69, Issue 2, Pages (August 2018)
Autoimmune hepatitis Journal of Hepatology
Volume 44, Pages S19-S24 (January 2006)
Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection  Anaïs Vallet-Pichard,
AST/platelet ratio index associates with progression to hepatic failure and correlates with histological fibrosis stage in Japanese patients with primary.
Cheng-Yuan Peng, Rong-Nan Chien, Yun-Fan Liaw  Journal of Hepatology 
European Association for the Study of the Liver  Journal of Hepatology 
Jean-Charles Nault, Peter R. Galle, Jens U. Marquardt 
Volume 69, Issue 1, Pages (July 2018)
Riccardo Lencioni, Fabio Piscaglia, Luigi Bolondi 
Acute-on chronic liver failure
Trends in the management and burden of alcoholic liver disease
The Model for End-Stage Liver Disease (MELD) Predicts Early and Late Outcomes of Cardiovascular Operations in Patients With Liver Cirrhosis  Naoto Morimoto,
Volume 42, Issue 2, Pages (February 2005)
Volume 61, Issue 1, Pages S69-S78 (November 2014)
Management of cirrhosis due to chronic hepatitis C
Genomic risk of hepatitis C-related hepatocellular carcinoma
Andres Cardenas, Pere Ginès  Journal of Hepatology 
Volume 57, Issue 4, Pages (October 2012)
Volume 66, Issue 2, Pages (February 2017)
Behzad Hajarizadeh, Jason Grebely, Gregory J. Dore 
Internal medicine L-4 Liver cirrhosis & portal hypertension
Epidemiology & First option of treatment
Volume 61, Issue 1, Pages S45-S57 (November 2014)
The heart in liver transplantation
Clinical states of cirrhosis and competing risks
Wolfgang Sieghart, Florian Hucke, Markus Peck-Radosavljevic 
Volume 140, Issue 5, Pages e2 (May 2011)
Molecular prognostication of liver cancer: End of the beginning
Volume 52, Issue 5, Pages (May 2010)
Chetana Lim, Chady Salloum, Daniel Azoulay
Non-invasive evaluation of liver fibrosis using transient elastography
Volume 63, Issue 1, Pages (July 2015)
Hepatorenal syndrome, MELD score and liver transplantation: An evolving issue with relevant implications for clinical practice  Paolo Angeli, Pere Gines 
Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence  Christian Toso, Gilles Mentha, Pietro.
Vincenzo Mazzaferro, Andrea Pulvirenti, Jorgelina Coppa 
Liver Transplantation for Hepatocellular Carcinoma
New trials and results in systemic treatment of HCC
Hepatitis C Virus Infection, Age, and Hispanic Ethnicity Increase Mortality From Liver Cancer in the United States  Zobair M. Younossi, Maria Stepanova 
Volume 60, Issue 6, Pages (June 2014)
Pathogenesis of cholestatic hepatitis C
Josep M. Llovet, Robert Montal, Augusto Villanueva 
Jordi Bruix, Maria Reig, Morris Sherman  Gastroenterology 
Volume 156, Issue 4, Pages (March 2019)
Reversion of disease manifestations after HCV eradication
Volume 60, Issue 6, Pages (June 2014)
Presentation transcript:

Liver cancer: Approaching a personalized care Jordi Bruix, Kwang-Hyub Han, Gregory Gores, Josep Maria Llovet, Vincenzo Mazzaferro  Journal of Hepatology  Volume 62, Issue 1, Pages S144-S156 (April 2015) DOI: 10.1016/j.jhep.2015.02.007 Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 1 BCLC staging and treatment strategy [as per Semin Liver Dis. 2014 Nov;34(4):444–55]. The figure represents the first approach to the evaluation of the patients with expected prognosis and initial treatment option to be considered. As shown, the upper part of the scheme defines prognosis according to the relevant clinical and tumor related parameters. Bottom part depicts the decision process to select a treatment option for first consideration. As in all recommendations, final treatment indication should take into account a detailed evaluation of additional characteristics (age, comorbidities) of the patients that imply a personalized decision making. ∗Note that Child-Pugh classification is not sensitive to accurately identify those patients with advanced liver failure that would deserve liver transplant consideration. Some patients fitting into Child-Pugh B, and even A, may present a poor prognosis because of clinical events not captured by such system, i.e. spontaneous bacterial peritonitis, recurrent variceal bleeding, refractory ascites with or without hepatorenal syndrome, recurrent encephalopathy, severe malnutrition. ∗∗Patients with end-stage cirrhosis due to heavily impaired liver function (Child-Pugh C or earlier stages with predictors of poor prognosis, high MELD score) should be considered for liver transplantation. In them, HCC may become a contraindication if exceeding the enlistment criteria. Journal of Hepatology 2015 62, S144-S156DOI: (10.1016/j.jhep.2015.02.007) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions

Fig. 2 Personalised decision making in a patient with HCC. (A) Macroscopic view of a resected HCC in a patient with cirrhosis due to HCV infection. Diagnosis was based on imaging techniques and its size was between 3 and 4cm. Liver function was preserved, but there was clinically significant portal hypertension (hepatic venous pressure gradient=11mmHg). Liver transplant was contraindicated because of comorbidities and its location protruding in the liver surface precluded safe ablation (direct access without a protective rim of non-tumoral liver is associated to increased risk of bleeding and peritoneal seeding). In addition, size >30mm is a predictor of incomplete ablation. Because of these considerations it was decided to recommend surgical resection through laparoscopy. (B) Partition of the HCC shows capsule formation and no macroscopic satellites. It is possible to differentiate the separate tumor areas and even some minute intratumoral nodules. There is a necrotic haemorrhagic area in the central part. This macroscopic heterogeneity (also identified by different differentiation degrees across the nodule) predicts a heterogeneous molecular profile if assessed by any of the currently available technologies. Increased proliferation markers will be present everywhere, but tumor needle biopsy will be at risk to fail to accurately inform about the tumor biology profile. Journal of Hepatology 2015 62, S144-S156DOI: (10.1016/j.jhep.2015.02.007) Copyright © 2015 European Association for the Study of the Liver Terms and Conditions